The lymphatic pathways of non-small cell lung cancer and their implication in curative irradiation treatment

Kiricuţă, I; Mueller, Gerd; Stiess, J; Bohndorf, W

doi:10.1016/0169-5002(94)90284-4

Cited by 24 publications

(24 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No oncological data exist to support this important change in the TNM classification. The survival of patients with SCLNM was similar with that with M1 disease, no patient survived longer than 3 years the diag- nosis of the SCLNM [10]. The data summarized by Emami & Perez [6] regarding the involvement of the SCLN in the Perez/Brady textbook also influenced the routine inclusion of these nodes in the irradiation fields (Table 5).…”

Section: Supraclavicular and Contralateral Hilar Lymph Node Metastasimentioning

confidence: 78%

“…The introduction of the N3 nodal status in the 1985 TNM classification was performed by Mountain [24] based only on the at the time usual management of these lymphatics (supraclavicular and contralateral hilar nodes) by the, as he wrote, "American radiotherapist". However, no oncological data support this decision [10][11][12][13][14].…”

Section: Historical Overview Of Tnm Classification and Field Selectiomentioning

confidence: 99%

See 1 more Smart Citation

Selection and Delineation of Lymph Node Target Volume for Lung Cancer Conformal Radiotherapy Proposal for Standardizing Terminology Based on Surgical Experience

Kiricuţă

2001

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Section: Supraclavicular and Contralateral Hilar Lymph Node Metastasimentioning

confidence: 78%

Section: Historical Overview Of Tnm Classification and Field Selectiomentioning

confidence: 99%

Selection and Delineation of Lymph Node Target Volume for Lung Cancer Conformal Radiotherapy Proposal for Standardizing Terminology Based on Surgical Experience

Kiricuţă

2001

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…A recent study has shown that there are wide variations in target volume definition for PORT even among TRT oncologists [71]. Based on previous studies, it seems reasonable to treat only involved lymph node stations and uninvolved stations at high risk to better protect surrounding normal structures and consequently minimize treatment-related mortality [40,50,72,73,74]. In the ongoing, phase III, randomized Lung Adjuvant Radiotherapy Trial (ART), the irradiation volume includes the lymph node stations involved according to the pathological report as well as the lymph node stations considered at high risk for involvement according to tumor location, with station 4 and station 7 and the homolateral hilar region always involved in the conformal treatment volume ( Fig.…”

Section: Implications For a New Trial Evaluating Portmentioning

confidence: 99%

“…Thus, if one considers a series of surgical patients with pN2 nodal disease, the risk for lymph node involvement is 48% around the trachea and 41% in the subcarenal region [70]. Consequently, paratracheal nodes, subcarenal nodes, as well as the homolateral hilar region should be systematically included in the irradiation volume [71,72]. A recent study has shown that there are wide variations in target volume definition for PORT even among TRT oncologists [71].…”

Section: Implications For a New Trial Evaluating Portmentioning

confidence: 99%

Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data

Péchoux

2011

The Oncologist

117

View full text Add to dashboard Cite

After completing this course, the reader will be able to: 1. Identify patients with non-small cell lung cancer who may benefit from postoperative radiotherapy based upon current evidence. 2. Summarize the results of analyses of both older and more recent data regarding postoperative radiotherapy in NSCLC patients. ABSTRACT In completely resected non-small cell lung cancer (NSCLC) patients with pathologically involved mediasti-nal lymph nodes (N2), administration of adjuvant platinum based chemotherapy is now considered the standard of care, based on level 1 evidence. The role of postoperative radiation therapy (PORT) in this group of patients remains controversial. The PORT meta-analysis published in 1998 concluded that adjuvant radiotherapy was detrimental to patients with early-stage completely resected NSCLC, but that the role of PORT in the treatment of tumors with N2 involvement was unclear, and that further research was warranted. Recent retrospective and non-randomized studies, as well as subgroup analyses of recent randomized trials evaluating adjuvant chemotherapy, provide evidence of the possible benefit of PORT in patients with mediastinal nodal involvement. The role of PORT is also a valid question in patients with proven N2 disease who have undergone only induction chemotherapy followed by surgery, because the local recurrence rate for such patients varies in the range of 20%-60%. Based on the currently available data, PORT should be discussed for fit patients with completely resected NSCLC with N2 nodal involvement, preferably after completion of adju-vant chemotherapy. There is a need for new randomized evidence to evaluate PORT using the modern three-dimensional conformal radiation technique, with attention paid to reducing the risk for, particularly, pulmonary and cardiac toxicity. A new large multi-institutional randomized trial evaluating PORT in this patient population is needed and now under way. The Oncologist 2011;16:672-681

show abstract

“…Lung cancer usually metastasizes to mediastinal lymph nodes. 4 Slaughter developed the theory of field cancerization in tumours of head and neck in 1946 where multiple tumours can originate independently in an area of epithelium pre-conditioned to cancer development by long-term exposure to carcinogens. 5 Patients with head and neck cancers have high (2-3%) incidence of second primary lesions.…”

Section: Discussionmentioning

confidence: 99%

Metastatic neck node: a straying journey to diagnosis

Galagali¹,

Singh

2018

Int J Otorhinolaryngol Head Neck Surg

View full text Add to dashboard Cite

<p class="abstract">Squamous cell carcinoma of lung is most commonly associated with smoking. Its metastasis to contralateral neck node as the first presenting symptom is very rare. Tuberculosis (TB) and cancer of lung have causal relationship. There may also be coexistence of another neoplasm around the time of diagnosis of primary neoplasm. We present a case report of an 80 years old man who presented with a contralateral metastatic neck node. He was diagnosed to have coexistent lung cancer and pulmonary TB. In this journey towards diagnosis, the findings suggestive of tubercular larynx might have been a sequel of pulmonary TB.</p>

show abstract

The lymphatic pathways of non-small cell lung cancer and their implication in curative irradiation treatment

Cited by 24 publications

References 11 publications

Selection and Delineation of Lymph Node Target Volume for Lung Cancer Conformal Radiotherapy Proposal for Standardizing Terminology Based on Surgical Experience

Selection and Delineation of Lymph Node Target Volume for Lung Cancer Conformal Radiotherapy Proposal for Standardizing Terminology Based on Surgical Experience

Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data

Metastatic neck node: a straying journey to diagnosis

Contact Info

Product

Resources

About